白雲山(00874.HK)擬向化學制藥(珠海)增資4.89億元
格隆匯11月24日丨白雲山(00874.HK)公佈,公司使用原募投項目“大南藥”生產基地一期建設項目的何濟公異地改造項目募集資金及利息約38,428.87萬元(人民幣,下同)及信息化平台建設項目(公司部分)募集資金及利息約10,472.50萬元,共計約48,901.37萬元通過全資子公司化學藥科技公司向募投項目實施主體、公司全資孫公司化學制藥(珠海)公司增資,用於化學制藥(珠海)公司建設項目。本次增資採用分期增資的方式,由公司董事會授權總經理辦公會根據該募投項目實施進度情況審議決定。
本次增資事項是基於公司實施相關募投項目建設需要,有利於提高募集資金使用效率,符合公司的發展戰略和長遠規劃,不會對公司產生不利影響。募集資金的使用方式、用途等符合公司主營業務發展方向,符合公司及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.